A network meta-analysis assessing endocrine side effects associated with immune checkpoint inhibitors in colorectal cancer
By
Boyu Chen
Jing Liu
Kexin Gan
Liqun Yang
Peng Qiu
Boqing Ma
Wen Chen
July 10, 2026
Clinical Scorecard: A network meta-analysis assessing endocrine side effects associated with immune checkpoint inhibitors in colorectal cancer
At a Glance
Category Detail
Condition Colorectal cancer (CRC) Key Mechanisms Immune checkpoint inhibitors (ICIs) block inhibitory checkpoints, enhancing T cell activity against tumors. Target Population Patients with advanced colorectal cancer, particularly those with high microsatellite instability or mismatch repair deficiency (MSI-H/dMMR). Care Setting Oncology clinics managing advanced colorectal cancer.
Key Highlights
ICI-based regimens are associated with a higher thyroid-related toxicity burden compared to conventional therapy. Pembrolizumab and ICI+tyrosine kinase inhibitor (TKI) significantly increase the risk of hypothyroidism. Hyperthyroidism risk is significantly higher with ICI+TKI and ICI plus chemotherapy plus an anti-angiogenic antibody. Grade 1–2 adverse events are consistently increased across ICI-based treatments. Endocrine adverse events often require long-term follow-up and management. Guideline-Based Recommendations
Diagnosis
Proactive endocrine monitoring is recommended during the first few months of ICI therapy. Management
Standardized management of endocrine irAEs is emphasized. Monitoring & Follow-up
Intensified monitoring for endocrine function is necessary early in treatment. Risks
About 10% of patients receiving ICIs may develop some form of endocrine dysfunction. Patient & Prescribing Data
Patients with advanced CRC receiving immune checkpoint inhibitors.
Endocrine adverse events can disrupt treatment continuity and impair quality of life.
Clinical Best Practices
Early recognition of endocrine irAEs is crucial. Long-term follow-up is necessary for patients with irreversible endocrine dysfunction. Related Resources & Content
